SEELOS THERAPEUTICS, INC.
DelistedCIK 1017491fmd_1FJAF307DX033VPJQQZ7N73G3NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2024, 58 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 9 | 5 | 6 | 1 | 0 | 0 | 0 | – | – | 2 |
| Cost of revenue | 1 | 1 | 1 | – | – | – | – | – | – | – |
| Gross profit | 8 | 4 | 2 | – | – | – | – | – | – | – |
| Research and development | 21 | 15 | 6 | 3 | 1 | 23 | 11 | 47 | 59 | 30 |
| Total operating expenses | 31 | 25 | 14 | 11 | 3 | 30 | 19 | 62 | 71 | 43 |
| Operating income | (23) | (21) | (14) | (11) | (3) | (30) | (19) | (62) | (71) | (40) |
| Interest expense | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 2 | 6 | (1) | (0) | (22) | (0) | (4) | (3) | 3 |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Net income from continuing operations | (22) | (19) | (8) | (12) | (9) | – | – | – | – | – |
| Net income | (22) | (19) | (7) | 0 | (3) | (51) | (19) | (66) | (74) | (38) |